Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.33 |
| ▸ | TUBB | P07437 | 2/20 | 0.33 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.33 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.33 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.33 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.33 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.33 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.33 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.33 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.33 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.33 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.33 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.33 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10013514 | 0.80 | TUBB4A (0.33) | ALDH1A1KDM4ETUBB4ATUBBTUBA3C | |
| SCHEMBL12436210 | 0.80 | ALDH1A1 (0.35) | ALDH1A1KDM4ETUBB4ATUBBTUBA3C | |
| SCHEMBL1400933 | 0.79 | MTNR1A (0.48) | ALDH1A1KDM4EMEN1KMT2AMTNR1A | |
| SCHEMBL850907 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KDM4EMEN1KMT2ACYP1A2 | |
| SCHEMBL3507485 | 0.78 | POLB (0.48) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL2095645 | 0.77 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL16535089 | 0.77 | TACR1 (0.31) | KMT2AHPGDTACR1 | |
| SCHEMBL465570 | 0.74 | TPMT (0.46) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL2092292 | 0.73 | TPMT (0.44) | ALDH1A1TACR1 | |
| SCHEMBL2092299 | 0.73 | CES2 (0.41) | TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-02-11 | — | — | US | disclosed |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-20 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | ALDH1A1 2293/4885KDM4E 142/4885MEN1 2750/4885 |
| US-20210040078-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | ALDH1A1 2293/4885KDM4E 142/4885MEN1 2750/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ALDH1A1 2293/4885KDM4E 142/4885MEN1 2750/4885 |
| US-10807974-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ALDH1A1 2293/4885KDM4E 142/4885MEN1 2750/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | ALDH1A1 2293/4885KDM4E 142/4885MEN1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.